Guanglin Xu

Dr. Guanglin Xu


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
WLWei Li
Wei Li
YCYuanyuan Cao
Yuanyuan Cao
JXJinling Xu
Jinling Xu
YWYing Wang
Ying Wang
WLWeijie Li
Weijie Li
GAGuizhen Ao
Guizhen Ao
Chemotherapy resistance remains a major challenge in cancer treatment. COX-2 (cyclooxygenase 2) is involved in drug resistance and poor prognosis of many neoplastic diseases or cancers. However, investigations identifying new modulators of COX-2 pathway and searching for new chemicals targeting these valid resistant biomarkers are still greatly needed. HCT15, HCT-116, HT-29, COLO205, FHC, IMCE, SW480 cell lines were used to detect the expression of YAP and COX-2. Site-directed mutagenesis, luciferase reporter analysis and ChIP assay were used to test whether YAP activated COX-2 transcription through interaction with TEAD binding sites in the promoter of COX-2. Cell line models exhibiting overexpression or knockdown of some genes were generated using transfection agents. Coimmunoprecipitation was used to detect protein mutual interaction. mRNA and protein levels were measured by qRT-PCR and western blot respectively. Here, we reported that both YAP and COX-2 were overexpressed in colorectal cancer cells. YAP increased COX-2 expression at the level of transcription requiring intact TEAD binding sites in the COX-2 promoter. YAP conferred drug resistance through COX-2 and its related effectors such as MCL, MDR, Survivin. GCCSysm-4 (G-4), a YAP and COX-2 inhibitor, effectively inhibited both YAP and COX-2 activation, induced apoptosis and decreased viability in Taxol-resistant cells. Inhibition of YAP and COX-2 acted synergistically and more efficiently reduced the resistance of CRC cells than either of them alone. Our data provide new mechanisms that YAP is a new upstream regulator of COX-2 pathway and plays an important role in conferring resistance in CRC cells. G-4, targeting YAP-COX-2, may be a novel valuable strategy to combat resistance in CRC.

1 April 2018 in Neoplasia
Verified
Journal Article
Open access
GXGuanglin Xu
Guanglin Xu
YWYing Wang
Ying Wang
WLWeijie Li
Weijie Li
YCYuanyuan Cao
Yuanyuan Cao
JXJinling Xu
Jinling Xu
YSYawen Sun
Yawen Sun
COX-2 and YAP are shown to be highly associated with hepatocellular carcinoma (HCC) and frequently upregulated during tumor formation. However, despite their importance, whether there is a mutual interaction between COX-2 and YAP and how they regulate each other are not clear. In this paper, we showed that COX-2 overexpression in HCC cell lines resulted in increased levels of YAP mRNA, protein, and its target genes. COX-2 promoted proliferation of HCC cell lines, and knockdown of YAP antagonized this effect. In addition, our results indicated that EP2 and Wnt/β-Catenin mediate the transcriptional induction of YAP by COX-2. On the other hand, YAP increased COX-2 expression at the level of transcription requiring intact TEAD binding sites in the COX-2 promoter. Collectively, these findings indicated that COX-2 is not only a stimulus of YAP but also a target of Hippo-YAP pathway, thus forming a positive feedback circuit, COX-2-PGE2-EP2-Gαs-β-catenin-YAP-COX-2. In a further study, we showed that inhibition of YAP and COX-2 acted synergistically and more efficiently reduced the growth of HCC cells and tumor formation than either of them alone, suggesting that dual governing of YAP and COX-2 may lead to the discovery of promising therapeutic strategies for HCC patients via blocking this positive feedback loop.

15 January 2023 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
YLYu Liao
Yu Liao
KHKejun Hu
Kejun Hu
WLWangwang Liu
Wangwang Liu
WWWei Wang
Wei Wang
HQHuanhuan Qiu
Huanhuan Qiu
GXGuanglin Xu
Guanglin Xu

1 January 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
LWLin Wang
Lin Wang
JWJing Wang
Jing Wang
YCYuanyuan Cao
Yuanyuan Cao
WLWeijie Li
Weijie Li
YWYing Wang
Ying Wang
GXGuanglin Xu
Guanglin Xu

18 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
GXGuanglin Xu
Guanglin Xu
JWJing Wang
Jing Wang
FWFangfang Wu
Fangfang Wu
NWNa Wang
Na Wang
WZWenli Zhou
Wenli Zhou
JYJiquan Yang
Jiquan Yang
YAP and 14-3-3γ are involved in HS-OA-induced growth inhibition of hepatocellular carcinoma cells: A novel mechanism for hydrogen sulfide releasing oleanolic acid YAP and 14-3-3γ are involved in HS-OA-induced growth inhibition of hepatocellular carcinoma cells: A novel mechanism for hydrogen sulfide releasing oleanolic acid

1 March 2005
Verified
Journal Article
Closed access
GXGuanglin Xu
Guanglin Xu
SYShu-Qin Yu
Shu-Qin Yu
ZGZhu-Nan Gong
Zhu-Nan Gong
SZShuan-Quan Zhang
Shuan-Quan Zhang